Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04173104 · ClinicalTrials.gov registry record · Early Phase 1
PET and MRI Imaging of Brain Tumors Using [18F]PARPi
A Early Phase 1 study of Brain Tumor and Brain Cancer, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 5
- Enrollment target
- 1
- Study location
NCT04173104 is a Early Phase 1 study of Brain Tumor and Brain Cancer that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 5 participants, below the 282-participant average among 69 other Brain Tumor trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04173104, a Early Phase 1 study of Brain Tumor and Brain Cancer, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 5 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is to collect data about how 18FPARPi can be used together with PET/positron emission tomography and MRI/magnetic resonance imaging scans to take pictures of brain cancer
Conditions Studied
Interventions
- DIAGNOSTIC_TEST PET/MR with [18F]PARPi
- DRUG [18F]PARPi
Study Locations (1)
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2019-11-01 |
| Est. Completion | 2026-02-05 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04173104
The ClinicalTrials.gov registry entry for NCT04173104 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 282-participant average among 69 other Brain Tumor trials with a reported enrollment target (98% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Brain Tumor appearing as the primary indexed condition, and to 2 interventions - of which PET/MR with [18F]PARPi is the first listed.
NCT04173104 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT04173104 about?
NCT04173104 is a clinical study titled "PET and MRI Imaging of Brain Tumors Using [18F]PARPi". This study is to collect data about how 18FPARPi can be used together with PET/positron emission tomography and MRI/magnetic resonance imaging scans to take pictures of brain cancer
What is the current status of trial NCT04173104?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 5 participants. The study started on 2019-11-01. Estimated completion is 2026-02-05.
What conditions does trial NCT04173104 study?
This clinical trial studies the following conditions: Brain Tumor, Brain Cancer.
What interventions are being tested in trial NCT04173104?
The interventions under investigation include: PET/MR with [18F]PARPi (DIAGNOSTIC_TEST), [18F]PARPi (DRUG).
Who is sponsoring clinical trial NCT04173104?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04173104 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma
RECRUITING · Early Phase 1
-
Comprehensive Evaluation of Tumor Oxygenation, Metabolism and Blood Supply of High Grade Glioma and Cervical Cancers Using Dynamic FAZA PET and Multiparametric MR
ACTIVE NOT RECRUITING · Early Phase 1
-
Tolerability and Activity of Brivaracetam (BRV) in Patients With Diffuse Gliomas
ACTIVE NOT RECRUITING · Early Phase 1
-
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
RECRUITING · Phase 1
-
A Comprehensive Clinical fMRI Software Solution to Enable Mapping of Critical Functional Networks and Cerebrovascular Reactivity in the Brain
RECRUITING
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.